Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Almonty Announces Intention to Relocate to the United States (click to learn more) Benton Intersects 22.0 m Grading 7.47% Copper Including 8.0 m Grading 11.93% Copper (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News HLS Therapeutics Inc T.HLS

Alternate Symbol(s):  HLTRF

Healthcare Industrials Auto Parts Drug Manufacturers - Major Diversified Industrials
HLS Therapeutics Inc. is a pharmaceutical company focused on the acquisition and commercialization of late-stage development, commercial stage promoted and established branded pharmaceutical products in the North American markets. It is engaged in addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease. It is also focused on products targeting the central... see more

Recent & Breaking News (TSX:HLS)

10 cheap healthcare stocks to buy now

Jonathon Brown November 11, 2024

HLS Therapeutics Announces Q3 2024 Financial Results

Canada NewsWire November 7, 2024

HLS Therapeutics to Host Q3 Fiscal 2024 Financial Results Conference Call

Canada NewsWire October 24, 2024

HLS Therapeutics to Present at H.C. Wainwright's 26th Annual Global Investment Conference

Canada NewsWire August 28, 2024

HLS Therapeutics Announces Q2 2024 Financial Results

Canada NewsWire August 8, 2024

HLS Announces Reimbursement for Vascepa® under Alberta's Provincial Drug Plan

Canada NewsWire July 29, 2024

HLS Therapeutics to Host Q2 Fiscal 2024 Financial Results Conference Call

Canada NewsWire July 25, 2024

HLS Therapeutics Announces the Sale of its XENPOZYME® Royalty Interest to DRI Healthcare Trust

Canada NewsWire July 2, 2024

HLS Therapeutics Reports Annual Meeting Results

Canada NewsWire June 7, 2024

New Study Published on the Impact of Pharmaceutical Support Programs on Persistence with Clozapine Treatment

Canada NewsWire May 28, 2024

HLS Therapeutics Announces Q1 2024 Financial Results

Canada NewsWire May 9, 2024

HLS Therapeutics to Host Q1 Fiscal 2024 Financial Results Conference Call

Canada NewsWire April 25, 2024

HLS Therapeutics to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference

Canada NewsWire April 9, 2024

New REDUCE-IT® Analyses Show VASCEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups

Canada NewsWire April 8, 2024

HLS Therapeutics Announces Fiscal 2023 Financial Results

Canada NewsWire March 14, 2024

HLS Therapeutics to Host Q4 and Fiscal 2023 Financial Results Conference Call

Canada NewsWire February 29, 2024

HLS Announces that Vascepa® is now reimbursed by British Columbia's Provincial Drug Plan

Canada NewsWire February 6, 2024

HLS Therapeutics Announces CFO Departure

Canada NewsWire December 18, 2023

New REDUCE-IT® Analyses Show Vascepa® (Icosapent Ethyl) Associated with 29 Percent Relative Risk Reduction Compared with Placebo in Prespecified Subgroup of Patients with Metabolic Syndrome, but Without Diabetes at Baseline

Canada NewsWire November 14, 2023

HLS Therapeutics Announces Q3 Fiscal 2023 Financial Results and Renewal of Normal Course Issuer Bid

Canada NewsWire November 9, 2023